Vaccine shows promising results for early-stage breast cancer patients
HER2-targeted dendritic cell vaccines stimulate immune responses and regression of HER2-expressing early-stage breast tumors
Date:
January 3, 2017
Source:
Moffitt Cancer Center
Summary:
Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient's own immune system to fight and kill cancer. Medical researchers are working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease.
Share:
AddThis Sharing Buttons
Share to FacebookShare to TwitterShare to Google+Share to LinkedInShare to MoreShare to Email
FULL STORY
Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer cells and target them for destruction. Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.
https://www.sciencedaily.com/releases/2017/01/170103122348.htm
